Prevention of contrast-induced AKI: a review of published trials and the design of the prevention of serious adverse events following angiography (PRESERVE) trial.

@article{Weisbord2013PreventionOC,
  title={Prevention of contrast-induced AKI: a review of published trials and the design of the prevention of serious adverse events following angiography (PRESERVE) trial.},
  author={Steven D. Weisbord and Martin Gallagher and James Kaufman and Alan Cass and Chirag R Parikh and Glenn M. Chertow and Kendrick A. Shunk and Peter A. McCullough and Michael J. Fine and Maria K. Mor and Robert A. Lew and Grant Huang and Todd A. Conner and Mary Therese Brophy and Joanne Lee and Susan Soliva and Paul M Palevsky},
  journal={Clinical journal of the American Society of Nephrology : CJASN},
  year={2013},
  volume={8 9},
  pages={1618-31}
}
Contrast-induced AKI (CI-AKI) is a common condition associated with serious, adverse outcomes. CI-AKI may be preventable because its risk factors are well characterized and the timing of renal insult is commonly known in advance. Intravenous (IV) fluids and N-acetylcysteine (NAC) are two of the most widely studied preventive measures for CI-AKI. Despite a multitude of clinical trials and meta-analyses, the most effective type of IV fluid (sodium bicarbonate versus sodium chloride) and the… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 13 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 28 extracted citations

Acute Kidney Injury: Culprits, Cures, and Consequences.

Circulation. Cardiovascular interventions • 2017
View 1 Excerpt

End Points for Clinical Trials in Acute Kidney Injury.

American journal of kidney diseases : the official journal of the National Kidney Foundation • 2017
View 1 Excerpt

Similar Papers

Loading similar papers…